html { overflow: visible; height: auto; } .MainNav_ItemWrapper:hover .Subnavigation_Wrapper, .MainNav_Item:focus + .Subnavigation_Wrapper { display: block; } .Header-FixedHeight .Dialoog, .Header-FixedHeight .Title_Wrapper, .Accordion_ContentContainer.Hidden { height: auto !important; visibility: visible; } .Dialoog_Step.Invisible, .Title_Wrapper.Invisible, main.Invisible, .js-GridItem { transform: none; opacity: 1; } .Dialoog_Form, .js-OptionsOpenBtn, .Image_Wrapper-Scaled, .Video_Wrapper-Scaled, img[data-src] { display: none; } .js-MasonryGrid { display: flex; flex-wrap: wrap; }

ga naar hoofdinhoud

Ga naar de website van Onco Oost

Endometriumcarcinoom

Zoeken

vul zoekwoord in

Studies Gynaecologische tumoren Endometriumcarcinoom

Fase 1

BI1479-0009 (Beamion PANTUMOR-1)

Solide tumoren, HER2-mutatie/amplificatie, fase 1 populatie, zongertinib

ELVN-002-003

HER2+ solide tumoren, fase 1, ELVN-002

IDeate-Pantumor 02

Solide tumoren, fase 1, infinatamab deruxtexan

Overig

DRUG access

Solide tumoren, EMA geregistreerde middelen

DRUP

Solide tumoren, ‘actionable’ moleculaire target

Endometriumcarcinoom

Fase 1

BI1479-0009 (Beamion PANTUMOR-1)

ELVN-002-003

IDeate-Pantumor 02

Overig

DRUG access

DRUP

Snel naar

Vademecum

Tumortypenetwerk

Studies

Nieuwe studie of wijziging doorgeven?